Original Article

You have full text access to this OnlineOpen article

Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts

  1. James J. Dignam PhD1,†,*,
  2. Lan Huang PhD2,
  3. Lynn Ries PhD2,
  4. Marsha Reichman PhD2,
  5. Angela Mariotto PhD2,
  6. Eric Feuer PhD2

Article first published online: 10 AUG 2009

DOI: 10.1002/cncr.24617

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5272–5283, 15 November 2009

Additional Information

How to Cite

Dignam, J. J., Huang, L., Ries, L., Reichman, M., Mariotto, A. and Feuer, E. (2009), Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts. Cancer, 115: 5272–5283. doi: 10.1002/cncr.24617

Author Information

  1. 1

    Department of Health Studies and Cancer Research Center, The University of Chicago, Chicago, Illinois

  2. 2

    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland

  1. †

    Fax: (773) 702-1979

*Department of Health Studies, 5841 South Maryland Avenue, MC 2007, The University of Chicago, Chicago, IL 60637

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 10 AUG 2009
  3. Manuscript Accepted: 27 APR 2009
  4. Manuscript Revised: 13 MAR 2009
  5. Manuscript Received: 4 NOV 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (898K)

References

  • 1
    Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961; 6: 101-121.
  • 2
    Henson DE, Ries LA. The relative survival rate. Cancer. 1995; 76: 1687-1688.
    Direct Link:
  • 3
    Elandt-Johnson R, Johnson NL. Survival Models and Data Analysis. New York, NY: John Wiley & Sons; 1980.
  • 4
    Percy C, Stanek E3rd, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health. 1981; 71: 242-250.
  • 5
    Percy CL, Miller BA, Gloeckler Ries LA. Effect of changes in cancer classification and the accuracy of cancer death certificates on trends in cancer mortality. Ann N Y Acad Sci. 1990; 609: 87-97.
    Direct Link:
  • 6
    Boer R, Ries LA, Ballegooijen M, et al. Ambiguities in calculating cancer patient survival: the SEER experience for colorectal and prostate cancer. Statistical Research and Applications Branch Technical Report No. 2002-05. Available at: http://srab.cancer.gov/reports. Accessed on July 28, 2009.
  • 7
    Miller AB, Yurgalevitch S, Weissfeld JL; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000; 21( 6 suppl): 400S-406S.
  • 8
    Remington RD. Who should code cause of death in a clinical trial? Control Clin Trials. 1984; 5: 241-244.
  • 9
    Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program 1988-2001, Patient and Tumor Characteristics. NIH Publication No. 07-6215. Bethesda, Md: SEER Program, National Cancer Institute; 2007.
  • 10
    Ries LAG, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology and End Results (SEER) Program. Oncologist. 2003; 8: 541-552.
  • 11
    Eaker S, Dickman PW, Hellstrom V, et al. Regional differences in breast cancer survival despite common guidelines. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2914-2918.
  • 12
    Woods LM, Rachet B, Cooper N, Coleman MP. Predicted trends in long-term breast cancer survival in England and Wales. Br J Cancer. 2007; 96: 1135-1138.
  • 13
    National Surgical Adjuvant Breast and Bowel Project (NSABP). NSABP website. Available at: http://www.nsabp.pitt.edu/. Accessed July 28, 2008.
  • 14
    Gamel JW, Vogel RL. Nonparametric comparison of relative versus cause-specific survival in Surveillance, Epidemiology and End Results (SEER) programme breast cancer patients. Stat Methods Med Res. 2001; 10: 339-352.
  • 15
    Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 1958; 8: 699-712.
  • 16
    National Center for Health Statistics (NCHS). NCHS website. Available at: http://www.cdc.gov/nchs/. Accessed July 28, 2008.
  • 17
    Ernster VL, Barclay J, Kerlikowske K, et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based Surveillance, Epidemiology, and End Results Program. Arch Int Med. 2000; 160: 953-958.
  • 18
    Hakulinen T. On long-term relative survival rates. J Chronic Dis. 1977; 30: 431-443.
  • 19
    Buckley JD. Additive and multiplicative models for relative survival rates. Biometrics. 1984; 40: 51-62.
  • 20
    Esteve J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of net survival: elements for further discussion. Stat Med. 1990; 9: 529-538.
    Direct Link:
  • 21
    Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004; 23: 51-64.
    Direct Link:
  • 22
    Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in 5 National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006; 24: 2028-2037.
  • 23
    Anderson SJ, Wapnir IL, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in 5 National Surgical Adjuvant Breast and Bowel Project protocols of node negative breast cancer. J Clin Oncol. 2009; 27: 2466–2473.
  • 24
    Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007; 25: 2127-2132.
  • 25
    Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005; 23: 8664-8670.
  • 26
    Sargent DJ, Patiyil S, Yothers G, et al. for the ACCENT Group. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007; 25: 4569-4574.
View Full Article (HTML) Get PDF (898K)